| Description |
EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer[1].
|
| Related Catalog |
|
| Target |
8.62 µM; 52.6 µM
|
| In Vitro |
EGFR-IN-59 (Compound 8c; 0-65.5 µM; 48 hours) shows cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) [1]. Cell Viability Assay Cell Line: A549; WI38 cells[1] Concentration: 0-65.5 µM Incubation Time: 48 hours Result: Showed potent cytotoxicity against A549 cell line (IC50 = 8.62 µM), and mild to moderate toxicity against WI38 (IC50 = 52.6 µM).
|
| References |
[1]. Noha H Amin, et al. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers. Bioorg Chem. 2020 Dec;105:104358.
|
